Best Medical Stocks For 2014

As part of ThinkAdvisor’s Special Report, 21 Days of Tax Planning Advice for 2014, throughout the month of March, we are partnering with our Summit Professional Networks sister service, Tax Facts Online, to take a deeper dive into certain tax planning issues in a convenient Q&A format.

Q: What is a health savings account (HSA) and who is eligible?

An HSA is a trust created exclusively for the purpose of paying qualified medical expenses of an account beneficiary.

An HSA must be created by a written governing instrument that states:

(1) no contribution will be accepted except in the case of a rollover contribution unless it is in cash or to the extent that the contribution, when added to previous contributions for the calendar year, exceeds the contribution limit for the calendar year;

(2) the trustee is a bank, an insurance company, or a person who satisfies IRS requirements;

(3) no part of trust assets will be invested in life insurance contracts;

Top 5 Information Technology Stocks To Invest In Right Now: Bacterin International Holdings Inc (BONE)

Bacterin International Holdings, Inc. (Bacterin), formerly K-Kitz, Inc., develops, manufactures and markets biologics products to domestic and international markets through Bacterin's biologics division. Its products are used in a variety of applications, including enhancing fusion in spine surgery, relief of back pain with a facet joint stabilization, promotion of bone growth in foot and ankle surgery, promotion of skull healing following neurosurgery and subcondral bone defect repair in knee and other joint surgeries. The Company has developed and manufacture and sell several human tissue-based products, primarily allografts, into the medical marketplace through its biologics division. In addition, it also manufactures and sells, directly under its own name and indirectly through distributors, various coating and surgical drain products through its medical devices division.

The Company�� medical devices division develops medical devices intended for use in several diverse clinical areas, including orthopedic, plastic, and cardiovascular surgery. The medical devices division also develops custom surgical instrument kits for use with allografts processed by its biologics division. The medical devices division actively develops intellectual property associated with its devices and coating platforms, for the purposes of protecting its Bacterin-branded devices and for use in alliance projects. The manufacturing and operations of the biologics and medical devices divisions are organized separately while products from both are marketed through several channels, including independent distributors, joint development projects and its direct sales network.

Biologics Division

The Company�� biologics products include OsteoSponge, OsteoSponge SC, OsteoWrap, OsteoLock and BacFast, as well as certain other allograft products, such as OsteoSponge, OsteoWrap, OsteoLock and BacFast and hMatrix. OsteoSponge is a form of demineralized bone matrix made from 100% human bone. Ost! eoSponge provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment. The malleable properties of OsteoSponge enable it to conform to, and fill, defects. Upon compressing the allograft, OsteoSponge springs back to completely fill the void. Its mechanical and biological properties make OsteoSponge an bone graft for use in various orthopedic practices, including spine, neurology, cranial/maxillofacial, trauma, plastic/reconstruction and general procedures where new bone growth is needed.

OsteoSponge SC is a form of OsteoSponge designed to be used in joint surgery. Bacterin has shown, in goat studies, the ability to re-generate cartilage in joint repair and believes that this product has the potential to significantly change the standard of care in human joint surgery. OsteoWrap is 100% human cortical bone demineralized through a process to make the graft flexible while maintaining allograft integrity. This product has various applications in orthopedic, neurological, trauma, oral/maxillofacial and reconstructive procedures. OsteoWrap can wrap around non-union fractures to assist with fusion, can act as a biologic plate or can be used in conjunction with a hardware plate system. Additionally, this product provides the surgeon with superior handling characteristics as the allograft can be easily sized using surgical scissors or a scalpel, and will withhold sutures or staples for fixation.

OsteoLock and BacFast are dowels made from human bone. BacFast HD, having the same design as OsteoLock, is optimized through its demineralization technology. OsteoLock and BacFast can be used to augment spinal procedures for mild spinal conditions. hMatrix dermal scaffold is an extension of Bacterin's core biologics technology and its third human acellular biological scaffold. hMatrix is an acellular matrix made from donated human dermal tissue that is used to replace a patient's damaged tissue. hMatrix provides a natural collagen tissue scaffold! that pro! motes cellular ingrowth, tissue vascularization and regeneration. The Company makes and sells sports allografts which are processed specifically for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction and meniscal repair; milled allografts, which are consists of cortical bone milled to desired shapes and dimensions, also called milled spinal allografts, and traditional allografts for multi-disciplinary applications, including orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary and plastic/reconstructive.

Medical Device Products

The Company�� medical devices division researches, tests and develops coatings for medical devices, particularly antimicrobial-based coatings. This division produces and distributes OsteoSelect DBM putty, an osteoinductive product used by surgeons as bone void filler in the extremities and pelvis. OsteoSelect DBM putty is engineered with the surgeon in mind. OsteoSelect can be molded into any shape and compressed into bony voids. Its medical devices division also develops custom surgical instrument kits for use with allografts processed by its biologics division. The Company sells a surgical drain series called ViaTM, which is used to drain exudate from a surgical site. Building upon the ViaTM platform, Bacterin plans on releasing a second generation product called the Elutia surgical drains, which will be performance enhanced through an antimicrobial coating to help reduce the incidence of surgical site infection.

The Company competes with Medtronic, DePuy, Synthes, Arthrex, Smith & Nephew, Nuvasive, OrthoFix, Biomet, Osteotech, Orthovita, MTF, Stryker, RTI, AlloSource, Lifenet Health, Integra, ConMed/Linvatec, Wright, Exactech, ArthroCare, Harvest and Arteriocyte.

Advisors' Opinion:

• [By Bryan Murphy]

  It may not be as big as NuVasive, Inc. (NASDAQ:NUVA), and it might not be as sexy as MiMedx Group Inc. (NASDAQ:MDXG). But, Bacterin International Holdings Inc. (NYSEMKT:BONE) offers something to investors that MDXG and NUVA don't - can't - right now... a distinct opportunity for a lot of upside in a short amount of time.

Best Medical Stocks For 2014: ResMed Inc (RMD)

ResMed Inc., (ResMed), incorporated on March 31, 1994, is a holding company for the ResMed Group. The Company, through its subsidiaries, is a developer, manufacturer and distributor of medical equipment for treating, diagnosing, and managing sleep-disordered breathing and other respiratory disorders. Sleep-disordered breathing (SDB) includes obstructive sleep apnea (OSA), and other respiratory disorders that occur during sleep. The Company has developed a number of products for SDB and other respiratory disorders including airflow generators, diagnostic products, mask systems, headgear and other accessories. Its manufacturing operations are located in Australia, Singapore, France, Germany, Malaysia and the United States. Its distribution and sales sites are located in the United States, Germany, France, the United Kingdom, Switzerland, Australia, Japan, Norway and Sweden. In December 2013, ResMed Inc acquired Unimedis SRO, a surgical appliance and manufacturing company.

Air Flow Generators

The Company produces continuous positive airway pressure (CPAP), variable positive airway pressure (VPAP) and AutoSet systems for the titration and treatment of SDB. The flow generator systems deliver positive airway pressure through a patient interface, either a small nasal mask, nasal pillows system, or full-face mask. Its VPAP units deliver bilevel therapy. There are two preset pressures: a higher pressure as the patient breathes in, and a lower pressure as the patient breathes out. AutoSet systems are based on a technology to monitor breathing and can also be used in the diagnosis, treatment and management of OSA. The Company�� Stellar 100 and 150 ventilation devices, provide both invasive and non invasive ventilation applications for adult and pediatric patients.

ResMed Inc.�� CPAP products include S8 Escape, S9 Elite and S9 Escape. Its VPAP products include VPAP III STA with QuickNav, VPAP S / VPAP IV, VPAP IV ST, S8 Auto 25, VPAP Tx Lab System, S9 VPAP S, S9 VPAP ST! , S9 VPAP Auto, S9 VPAP Adapt, S9 AutoSet CS, S9 Auto 25 and S9 VPAP COPD. The Company�� automatic positive airway pressure products include S9 AutoSet and S9 Escape Auto. Its ventilation products include Elisee 150, VS III and Stellar 100 and 150.

Masks, Accessories, Motors and Diagnostic Products

Masks, accessories, motors and diagnostic products together accounted for approximately 46% of its net revenues in fiscal 2012. Its Mask products include Activa LT, Swift LT for Her, Swift FX, Mirage SoftGel, Quattro FX, Swift FX for Her, Mirage FX, Mirage FX for Her, Pixi Pediatric Mask, Quattro FX for Her, Swift FX Bella, Quattro Air and Swift FX Nano. Its diagnostic products includes ApneaLink + Oximetry and ApneaLink Plus (U.S.)

Accessories and Other Products

The Company to assist those professionals diagnosing or managing the treatment of patients have data communications and control products, such as the EasyCare, ResLink, ResControl, ResControl II, TxControl, ResScan and ResTraxx modules that facilitate the transfer of data and other information to and from the flow generators. These products include humidifiers, such as H5i and H4i, which connect directly with the CPAP, VPAP and AutoSet flow generators to humidify and heat the air delivered to the patient, helping to prevent the drying of nasal passages that can cause discomfort. Other optional accessories include cold passover humidifiers, carry bags and breathing circuits. The Company�� data/patient management products include S9 Embletta Adapter, ResScan v3.14, ResTraxx v17.1., ResTraxx v18.3, ResScan v3.16 and EasyCare 1.0.

The Company competes with Philips BV, DeVilbiss Healthcare., Fisher & Paykel Healthcare Corporation Limited, Apex Medical Corp, BMC Medical Co. Ltd and Weinmann Gerate fur Medizin GmbH + Co. KG.

Advisors' Opinion:

• [By Seth Jayson]

  Basic guidelines
  In this series, I examine inventory using a simple rule of thumb: Inventory increases ought to roughly parallel revenue increases. If inventory bloats more quickly than sales grow, this might be a sign that expected sales haven't materialized. Is the current inventory situation at ResMed (NYSE: RMD  ) out of line? To figure that out, start by comparing the company's inventory growth to sales growth. How is ResMed doing by this quick checkup? At first glance, pretty well. Trailing-12-month revenue increased 10.0%, and inventory decreased 9.3%. Comparing the latest quarter to the prior-year quarter, the story looks decent. Revenue increased 9.9%, and inventory shrank 9.3%. Over the sequential quarterly period, the trend looks healthy. Revenue grew 1.9%, and inventory dropped 14.5%.

• [By Damian Illia]

  A Delaware corporation formed in 1994, ResMed Inc. (RMD) is a global leading designer, developer, manufacturer and marketer of medical products for the diagnosis, treatment and management of sleep-disordered breathing (SDB) and other respiratory disorders. For the quarter ended in Dec. 31, 2013 ResMed reported a 2 percent increase (a 1 percent increase in constant currency basis) in revenue over the quarter ended in Dec. 31, 2012. However, these earnings failed to meet analyst estimates; and not without a reason. A relatively poor performance was expected due to continued pressure in the United States, especially as a consequence of the market's restructuring due to competitive Medicare bidding. This might also be one of the reasons why this stock still remains undervalued.

• [By Anna Prior]

  ResMed Inc.(RMD) seems like a solid growth stock, but March sales reportedly were aided by a quarter-end deal with a large customer, while profit was boosted by noncash accruals, according to Barron’s. The strains evident in march-quarter results may grow, if Medicare and other insurers decide to pay a bundled price for continuous positive airway pressure treatments. Shares slipped 3.8% to $50.49 in recent trading.

Best Medical Stocks For 2014: Acceleron Pharma Inc (XLRN)

Acceleron Pharma Inc., incorporated on June 13, 2003, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of protein therapeutics for cancer and rare diseases. The Company�� research focuses on the biology of the Transforming Growth Factor-Beta (TGF-b) protein superfamily, a large and diverse group of molecules that are key regulators in the growth and repair of tissues throughout the human body. By coupling its discovery and development expertise, including its knowledge of the TGF-b superfamily, with its internal protein engineering and manufacturing capabilities, it has built a productive research and development platform that has generated clinical and preclinical protein therapeutic candidates with mechanisms of action.

The Company focuses on discovering and developing protein therapeutics that target a group of approximately 30 secreted proteins, or ligands, that are collectively referred to as the TGF-b superfamily. These ligands bind to subsets of 12 different receptors on the surface of cells, triggering intra-cellular changes in gene expression that guide cell growth and differentiation. The TGF-b superfamily ligands and their receptors represent an under-explored and diverse set of drug targets with the potential to yield therapeutics that modulate the growth and repair of diseased cells and tissues.

The Company has three internally discovered protein therapeutic candidates that are being studied in 12 ongoing Phase 2 clinical trials, focused on cancer and rare diseases. The Company�� two advanced protein therapeutic candidates, sotatercept and ACE-536, promote red blood cell production through a novel mechanism. Together with its collaboration partner, Celgene Corporation, the Company is developing sotatercept and ACE-536 to treat anemia and associated complications in patients with b-thalassemia and myelodysplastic syndromes (MDS). These red blood cell disorders are generally unresponsive to approved dru! gs. The Company�� third clinical stage protein therapeutic candidate, dalantercept, is designed to inhibit blood vessel formation through a mechanism that is distinct from, and potentially synergistic with, the dominant class of cancer drugs that inhibit blood vessel formation, the vascular endothelial growth factor (VEGF) pathway inhibitors. The Company is developing dalantercept primarily for use in combination with these products to produce better outcomes for cancer patients.

The Company and Celgene have conducted six human clinical trials with sotatercept in over 160 healthy volunteers and cancer patients. The Company has conducted one clinical trial with ACE-536 in healthy volunteers. In these studies, both sotatercept and ACE-536 caused a dose-dependent increase in the number of red blood cells. Based on these results, the Company and Celgene have initiated Phase II clinical trials with each of these protein therapeutic candidates in b-thalassemia and MDS. In the ongoing trial of sotatercept in patients with b-thalassemia, the Company has observed encouraging, dose-dependent increases in hemoglobin in a subset of patients at the two lowest dose levels.

Sotatercept is a soluble receptor fusion protein consisting of the extracellular domain of the activin receptor type IIA (ActRIIA) linked to the Fc domain of human IgG1. Sotatercept acts as a protein trap for TGF-b superfamily ligands that signal through the ActRIIA receptor. Sotatercept has increased red blood cells in multiple clinical trials. ACE-536 is a soluble receptor fusion protein consisting of a modified extracellular domain of the activin receptor type IIB (ActRIIB) linked to the Fc domain of human IgG1.

Advisors' Opinion:

• [By Jake L'Ecuyer]

  Shares of Acceleron Pharma (NASDAQ: XLRN) got a boost, shooting up 16.39 percent to $39.42 after Form 8-K for Acceleron Pharma showed that Celgene (NASDAQ: CELG) will buy 1.1 million shares for $47.15 million.

Best Medical Stocks For 2014: Covidien PLC (COV)

Covidien Public Limited Company is engaged in the development, manufacture and sale of healthcare products for use in clinical and home settings. It operates its businesses through three segments: Medical Devices, which includes the development, manufacture and sale of endomechanical instruments, energy devices, soft tissue repair products, vascular products, oximetry and monitoring products, airway and ventilation products; Pharmaceuticals, which includes the development, manufacture and distribution of specialty pharmaceuticals and active pharmaceutical ingredients, and Medical Supplies, SharpSafety products and original equipment manufacturer products. In May 2012, it acquired Newport Medical Instruments, Inc. In May 2012, it acquired superDimension, Ltd. In June 2012, the Company acquired Oridion Systems Ltd. In October 2012, its Mallinckrodt acquired CNS Therapeutics, Inc. In January 2013, the Company acquired CV Ingenuity. Advisors' Opinion:

• [By Jon C. Ogg]

  Covidien Ltd. (NYSE: COV) was started as Buy at Needham & Co.

  Halliburton Co. (NYSE: HAL) was reinstated as Outperform and added to the U.S. Focus List with a new price target of $58 (versus $48.30 now) at Credit Suisse, and it was reiterated as Buy and the price target was raised to $63 from $58 by Sterne Agee.

• [By Rich Duprey]

  With the spinoff complete from Covidien (NYSE: COV  ) effective June 28, the medical device manufacturer's�former specialty pharmaceutical arm,�Mallinckrodt, begins its new life today as an independently traded public company. It is listed on the NYSE under the symbol MNK.